Recent breakthroughs in the treatment of chronic hepatitis Delta.
NAP
bulevirtide
hepatitis D
lonafarnib
peg-IFN
Journal
Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
04
2022
accepted:
11
05
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.
Identifiants
pubmed: 35693059
doi: 10.53854/liim-3002-5
pii: 1124-9390_30_2_2022_204-210
pmc: PMC9177179
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
204-210Informations de copyright
Copyright © 2016 - 2022 InfezMed.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no potential conflicts of interest.
Références
Clin Transplant. 2007 Mar-Apr;21(2):258-64
pubmed: 17425755
Semin Liver Dis. 2012 Aug;32(3):195-200
pubmed: 22932967
Infect Dis (Lond). 2020 Aug;52(8):557-562
pubmed: 32401092
J Virol. 2002 Oct;76(20):10465-72
pubmed: 12239323
Semin Liver Dis. 2012 Aug;32(3):228-36
pubmed: 22932971
Hepatology. 2014 Jul;60(1):87-97
pubmed: 24585488
Hepatol Commun. 2020 Nov 13;5(2):189-202
pubmed: 33553968
J Infect Dis. 2018 May 25;217(12):1902-1906
pubmed: 29800369
Hepatology. 1991 Jun;13(6):1052-6
pubmed: 2050321
Gut Pathog. 2021 Oct 30;13(1):66
pubmed: 34717740
Molecules. 2010 Jul 07;15(7):4773-83
pubmed: 20657392
J Hepatol. 2019 May;70(5):1008-1015
pubmed: 30982526
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889
pubmed: 28964701
N Engl J Med. 2011 Jan 27;364(4):322-31
pubmed: 21268724
Lancet Infect Dis. 2019 Mar;19(3):275-286
pubmed: 30833068
Liver. 1995 Feb;15(1):45-52
pubmed: 7776857
Int J Antimicrob Agents. 2019 Dec;54(6):697-701
pubmed: 31541699
J Hepatol. 2022 Jul;77(1):254-255
pubmed: 35306059
Arq Gastroenterol. 2018 Jan-Mar;55(1):14-17
pubmed: 29561969
Aliment Pharmacol Ther. 2019 Apr;49(8):1071-1076
pubmed: 30793345
J Hepatol. 2016 Apr;64(1 Suppl):S102-S116
pubmed: 27084031
Gastroenterology. 2004 Jun;126(7):1740-9
pubmed: 15188169
J Hepatol. 2021 May;74(5):1200-1211
pubmed: 33484770
J Clin Invest. 2003 Aug;112(3):407-14
pubmed: 12897208
N Engl J Med. 1994 Jan 13;330(2):88-94
pubmed: 8259188
Hepatology. 2018 Apr;67(4):1224-1236
pubmed: 29152762
Lancet Infect Dis. 2015 Oct;15(10):1167-1174
pubmed: 26189433
Aliment Pharmacol Ther. 2021 Sep;54(5):583-605
pubmed: 34287994
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Hepatol Int. 2020 Sep;14(5):869-880
pubmed: 32895876
Antiviral Res. 2016 Sep;133:32-40
pubmed: 27400989
Dig Liver Dis. 2019 Mar;51(3):438-442
pubmed: 30314950
Hepatology. 2006 Sep;44(3):713-20
pubmed: 16941685
Antivir Ther. 2013;18(3 Pt B):541-8
pubmed: 23792471
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875